{"organizations": [], "uuid": "24bd18f7a9c0fb14b1d57071bf200586ffc7abb9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-european-commission-approves-adcet/brief-european-commission-approves-adcetris-for-cd30-positive-cutaneous-t-cell-lymphoma-idUSFWN1PH0NU", "country": "US", "domain_rank": 408, "title": "BRIEF-European Commission Approves Adcetris For CD30-Positive Cutaneous T-Cell Lymphoma", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-22T15:29:00.000+02:00", "replies_count": 0, "uuid": "24bd18f7a9c0fb14b1d57071bf200586ffc7abb9"}, "author": "", "url": "https://www.reuters.com/article/brief-european-commission-approves-adcet/brief-european-commission-approves-adcetris-for-cd30-positive-cutaneous-t-cell-lymphoma-idUSFWN1PH0NU", "ord_in_thread": 0, "title": "BRIEF-European Commission Approves Adcetris For CD30-Positive Cutaneous T-Cell Lymphoma", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-european commission", "sentiment": "negative"}, {"name": "cutaneous t-cell lymphoma reuters", "sentiment": "none"}, {"name": "takeda pharmaceutical co ltd", "sentiment": "none"}, {"name": "takeda", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "takeda pharmaceutical co ltd", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "ec", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 22, 2018 / 1:30 PM / Updated 8 minutes ago BRIEF-European Commission Approves Adcetris For CD30-Positive Cutaneous T-Cell Lymphoma Reuters Staff 1 Min Read \nJan 22 (Reuters) - Takeda Pharmaceutical Co Ltd: \n* EUROPEAN COMMISSION APPROVES ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA AFTER ONE PRIOR SYSTEMIC THERAPY– PROVIDING AN INNOVATIVE TREATMENT OPTION TO PATIENTS \n* TAKEDA PHARMACEUTICAL- PHASE 3 ALCANZA STUDY DEMONSTRATED HIGHLY STATISTICALLY SIGNIFICANT IMPROVEMENT IN RATE OF OBJECTIVE RESPONSE LASTING ATLEAST 4 MONTHS \n* TAKEDA PHARMACEUTICAL CO LTD - EUROPEAN COMMISSION EXTENDED CURRENT CONDITIONAL MARKETING AUTHORIZATION OF ADCETRIS \n* TAKEDA PHARMACEUTICAL- EC APPROVED ADCETRIS FOR TREATMENT OF ADULT PATIENTS WITH CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA AFTER AT LEAST 1 PRIOR SYSTEMIC THERAPY Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-22T15:29:00.000+02:00", "crawled": "2018-01-22T16:02:36.003+02:00", "highlightTitle": ""}